-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Moderna Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$274.49M | $17.74B | $19.26B | $6.85B |
| Cost of Revenue |
|
$7.93M | $2.62B | $5.42B | $4.69B |
| Gross Profit |
|
$266.56M | $15.12B | $13.85B | $2.16B |
| Research & Development |
|
$1.37B | $1.99B | $3.30B | $4.85B |
| Selling,General & Administrative |
|
$188.27M | $567.00M | $1.13B | $1.55B |
| Operating Expense |
|
$1.03B | $1.82B | $4.43B | $6.30B |
| Operating Income |
|
-$763.14M | $13.30B | $9.42B | -$4.24B |
| Net Income |
|
-$747.06M | $12.20B | $8.36B | -$4.71B |
Moderna Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$4.61B | $10.73B | $9.90B | $8.60B |
| Inventories |
|
$47.00M | $1.44B | $949.00M | $202.00M |
| Total Current Assets |
|
$6.30B | $16.07B | $13.43B | $10.33B |
| Property,Plant and Equipment |
|
$387.00M | $1.38B | $2.14B | $2.66B |
| Goodwill |
|
- | - | - | $52.00M |
| Total Assets |
|
$7.34B | $24.67B | $25.86B | $18.43B |
| Total Liabilities |
|
$4.78B | $10.52B | $6.74B | $4.57B |
| Retained Earnings |
|
-$2.24B | $9.96B | $18.32B | $13.61B |
| Total Shareholder Equity |
|
$2.56B | $14.15B | $19.12B | $13.85B |
| Common Stock |
|
- | - | - | - |
Moderna Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$31.25M | $232.00M | $348.00M | $621.00M |
| Dividends Payout |
|
- | - | - | - |
| Capital Expenditures (Capex) |
|
-$67.45M | -$284.00M | -$400.00M | -$707.00M |
| Free Cash Flow (FCF) |
|
$1.96B | $13.34B | $4.58B | -$3.83B |
Moderna Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$266.56M | $15.12B | $13.85B | $2.16B |
| Gross Profit Margin (%) |
|
97.11% | 85.24% | 71.88% | 31.47% |
| Operating Income |
|
-$763.14M | $13.30B | $9.42B | -$4.24B |
| Operating Income Margin (%) |
|
-278.02% | 74.97% | 48.90% | -61.90% |
| Net Income |
|
-$747.06M | $12.20B | $8.36B | -$4.71B |
| Net Income Margin (%) |
|
-272.16% | 68.80% | 43.41% | -68.84% |
| EBITDA |
|
-$732.00M | $13.53B | $9.77B | -$3.28B |
| EBITDA Margin (%) |
|
-278.02% | 74.97% | 50.71% | -47.94% |
Moderna Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
-29.17% | 86.26% | 43.73% | -34.03% |
| Return on Assets (ROA) |
|
-10.18% | 49.46% | 32.34% | -25.58% |
| Debt to Equity |
|
- | 6.19% | 0.25% | - |
| Debt to total asset |
|
- | 3.55% | 0.19% | - |
| Enterprise value to revenue |
|
135.57 | 5.38 | 3.51 | 5.30 |
| Enterprise value to EBITDA |
|
-50.84 | 7.06 | 6.92 | -11.06 |
| Enterprise value |
|
$37.21B | $95.51B | $67.57B | $36.33B |
| Cash to Debt |
|
- | 1,554.79% | 10,377.08% | - |
| Tax Rate (%) |
|
-0.34% | 8.15% | 12.67% | -19.58% |
| Payout Ratio |
|
- | - | - | - |
Related company
